ATE359785T1 - Manteltablette enthaltend nikotinsäure oder einen stoff, der zu nikotinsäure metabolisiert wird, in verzögert freigesetzter form, und einen hmg-coa reduktasehemmer im mantel zur sofortigen freisetzung - Google Patents

Manteltablette enthaltend nikotinsäure oder einen stoff, der zu nikotinsäure metabolisiert wird, in verzögert freigesetzter form, und einen hmg-coa reduktasehemmer im mantel zur sofortigen freisetzung

Info

Publication number: ATE359785T1
Authority: AT; Austria
Prior art keywords: nicotinic acid; nicotinamide; methyl; hmg; coa reductase
Prior art date: 1997-07-31

Application number

AT98938228T

Other languages

English (en)

Inventor

David J Bova

Josephine Dunne

Original Assignee

Kos Life Sciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-07-31

Filing date

1998-07-31

Publication date

2007-05-15

1998-07-31 Application filed by Kos Life Sciences Inc filed Critical Kos Life Sciences Inc

2007-05-15 Application granted granted Critical

2007-05-15 Publication of ATE359785T1 publication Critical patent/ATE359785T1/de

Links

PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 title abstract 10
239000011664 nicotinic acid Substances 0.000 title abstract 6
229960003512 nicotinic acid Drugs 0.000 title abstract 6
235000001968 nicotinic acid Nutrition 0.000 title abstract 5
229940121710 HMGCoA reductase inhibitor Drugs 0.000 title abstract 2
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title abstract 2
239000012729 immediate-release (IR) formulation Substances 0.000 title abstract 2
230000003111 delayed effect Effects 0.000 title 1
239000000126 substance Substances 0.000 title 1
-1 6-OH-nicotinamide Chemical compound 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
IMRLNFKFNFLWQF-IYKITFJXSA-N sorbinicate Chemical compound O([C@H](COC(=O)C=1C=NC=CC=1)[C@@H](OC(=O)C=1C=NC=CC=1)[C@H](OC(=O)C=1C=NC=CC=1)[C@H](COC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)C(=O)C1=CC=CN=C1 IMRLNFKFNFLWQF-IYKITFJXSA-N 0.000 abstract 2
206010072268 Drug-induced liver injury Diseases 0.000 abstract 1
208000021642 Muscular disease Diseases 0.000 abstract 1
201000009623 Myopathy Diseases 0.000 abstract 1
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 abstract 1
KTLRWTOPTKGYQY-UHFFFAOYSA-N N-methyl-4-pyridone-3-carboxamide Chemical compound CN1C=CC(=O)C(C(N)=O)=C1 KTLRWTOPTKGYQY-UHFFFAOYSA-N 0.000 abstract 1
ZYVXHFWBYUDDBM-UHFFFAOYSA-N N-methylnicotinamide Chemical compound CNC(=O)C1=CC=CN=C1 ZYVXHFWBYUDDBM-UHFFFAOYSA-N 0.000 abstract 1
KUEUWHJGRZKESU-UHFFFAOYSA-N Niceritrol Chemical compound C=1C=CN=CC=1C(=O)OCC(COC(=O)C=1C=NC=CC=1)(COC(=O)C=1C=NC=CC=1)COC(=O)C1=CC=CN=C1 KUEUWHJGRZKESU-UHFFFAOYSA-N 0.000 abstract 1
USSFUVKEHXDAPM-UHFFFAOYSA-N Nicotinamide N-oxide Chemical compound NC(=O)C1=CC=C[N+]([O-])=C1 USSFUVKEHXDAPM-UHFFFAOYSA-N 0.000 abstract 1
206010039020 Rhabdomyolysis Diseases 0.000 abstract 1
DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
229940056243 aluminium nicotinate Drugs 0.000 abstract 1
NSFYKDVWNTWJOK-UHFFFAOYSA-K aluminum;pyridine-3-carboxylate Chemical compound [Al+3].[O-]C(=O)C1=CC=CN=C1.[O-]C(=O)C1=CC=CN=C1.[O-]C(=O)C1=CC=CN=C1 NSFYKDVWNTWJOK-UHFFFAOYSA-K 0.000 abstract 1
239000011248 coating agent Substances 0.000 abstract 1
238000000576 coating method Methods 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
238000013265 extended release Methods 0.000 abstract 1
150000002632 lipids Chemical class 0.000 abstract 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
229960000827 niceritrol Drugs 0.000 abstract 1
NPORIZAYKBQYLF-LREBCSMRSA-N nicotinyl alcohol tartrate Chemical compound OCC1=CC=CN=C1.OC(=O)[C@H](O)[C@@H](O)C(O)=O NPORIZAYKBQYLF-LREBCSMRSA-N 0.000 abstract 1
229960000839 nicotinyl alcohol tartrate Drugs 0.000 abstract 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
210000002966 serum Anatomy 0.000 abstract 1
229950007581 sorbinicate Drugs 0.000 abstract 1
238000013268 sustained release Methods 0.000 abstract 1
239000012730 sustained-release form Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Child & Adolescent Psychology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Enzymes And Modification Thereof (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

AT98938228T 1997-07-31 1998-07-31 Manteltablette enthaltend nikotinsäure oder einen stoff, der zu nikotinsäure metabolisiert wird, in verzögert freigesetzter form, und einen hmg-coa reduktasehemmer im mantel zur sofortigen freisetzung ATE359785T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US90375297A	1997-07-31	1997-07-31

Publications (1)

Publication Number	Publication Date
ATE359785T1 true ATE359785T1 (de)	2007-05-15

Family

ID=25418027

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT07003276T ATE451926T1 (de)	1997-07-31	1998-07-31	Zusammensetzung enthaltend einen hmg-coa- reduktasehemmer und eine nikotinsäureverbindung zur behandlung von hyperlipidämie
AT98938228T ATE359785T1 (de)	1997-07-31	1998-07-31	Manteltablette enthaltend nikotinsäure oder einen stoff, der zu nikotinsäure metabolisiert wird, in verzögert freigesetzter form, und einen hmg-coa reduktasehemmer im mantel zur sofortigen freisetzung

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT07003276T ATE451926T1 (de)	1997-07-31	1998-07-31	Zusammensetzung enthaltend einen hmg-coa- reduktasehemmer und eine nikotinsäureverbindung zur behandlung von hyperlipidämie

Country Status (16)

Country	Link
US (3)	US20040053975A1 (de)
EP (2)	EP1017390B1 (de)
JP (2)	JP4870869B2 (de)
AT (2)	ATE451926T1 (de)
AU (1)	AU752673B2 (de)
BR (1)	BR9815548A (de)
CA (1)	CA2298549C (de)
CY (1)	CY1107057T1 (de)
DE (2)	DE69837610T2 (de)
DK (1)	DK1017390T3 (de)
ES (2)	ES2336492T3 (de)
IL (2)	IL134271A0 (de)
NO (1)	NO20000439L (de)
NZ (1)	NZ520176A (de)
PT (1)	PT1017390E (de)
WO (1)	WO1999006035A2 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IE970731A1 (en) †	1997-10-07	2000-10-04	Fuisz Internat Ltd	Product and method for the treatment of hyperlipidemia
DE19858789A1 (de) *	1998-12-18	2000-06-21	Bayer Ag	Kombination von Cerivastatin und Fibraten
US6569461B1 (en)	1999-03-08	2003-05-27	Merck & Co., Inc.	Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
AU774636B2 (en) *	1999-07-14	2004-07-01	Genzyme Corporation	Fat-binding polymers, optionally combined with lipase inhibitors
JP2001131151A (ja) *	1999-11-02	2001-05-15	Shionogi & Co Ltd	オレフィン誘導体の新規用途
IL139450A0 (en) *	1999-11-10	2001-11-25	Pfizer Prod Inc	Methods of administering apo b-secretion/mtp inhibitors
WO2001093859A1 (en) †	2000-06-09	2001-12-13	Lek Pharmaceuticals D.D.	Stable pharmaceutical product and formulation
WO2002034261A1 (en) *	2000-10-23	2002-05-02	Sankyo Company, Limited	Compositions for improving lipids in blood
US6916849B2 (en)	2000-10-23	2005-07-12	Sankyo Company, Limited	Compositions for improving lipid content in the blood
CA2428204A1 (en) *	2000-11-07	2002-05-16	Sankyo Company, Limited	Lipid peroxide-lowering compositions
TWI284529B (en) *	2000-12-18	2007-08-01	Sankyo Co	A composition for lowering triglyceride
US6982251B2 (en)	2000-12-20	2006-01-03	Schering Corporation	Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en)	2001-01-26	2006-07-04	Schering Corporation	Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
PT1355644E (pt)	2001-01-26	2006-11-30	Schering Corp	Utilização de compostos azetidinona substituídos para o tratamento de sitosterolemia
ES2274013T3 (es)	2001-01-26	2007-05-16	Schering Corporation	Combinaciones de activador(es) del receptor activado por el proliferador de los peroxisomas (ppar) e inhibidor(es)m de la absorcion de estelores y tratamientos para trastornos vasculares.
US7053080B2 (en)	2001-09-21	2006-05-30	Schering Corporation	Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
JP2005504091A (ja)	2001-09-21	2005-02-10	シェーリング　コーポレイション	ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
US7056906B2 (en)	2001-09-21	2006-06-06	Schering Corporation	Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
ITMI20012366A1 (it) *	2001-11-09	2003-05-09	Farmatron Ltd	Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali
US7176310B1 (en)	2002-04-09	2007-02-13	Ucb Sa	Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents
JP4607436B2 (ja) *	2002-08-02	2011-01-05	第一三共株式会社	ＨＭＧ−ＣｏＡリダクターゼ阻害剤を含有する医薬組成物
WO2004012740A1 (ja) *	2002-08-02	2004-02-12	Sankyo Company, Limited	HMG-CoAリダクターゼ阻害剤を含有する医薬組成物
CN100415235C (zh) *	2002-08-02	2008-09-03	三共株式会社	含有HMG-CoA还原酶抑制剂的药物组合物
US7560449B2 (en)	2002-11-06	2009-07-14	Schering Corporation	Methods and therapeutic combinations for the treatment of demyelination
SI21402A (sl)	2003-02-12	2004-08-31	LEK farmacevtska dru�ba d.d.	Obloženi delci in farmacevtske oblike
US7459442B2 (en)	2003-03-07	2008-12-02	Schering Corporation	Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
ES2311806T3 (es)	2003-03-07	2009-02-16	Schering Corporation	Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
WO2004081003A1 (en)	2003-03-07	2004-09-23	Schering Corporation	Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholeterolemia
EP1606287B1 (de)	2003-03-07	2013-10-02	Merck Sharp & Dohme Corp.	Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
AR041089A1 (es) *	2003-05-15	2005-05-04	Merck & Co Inc	Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
CA2534371A1 (en) *	2003-08-04	2005-02-10	Pfizer Products Inc.	Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
JP2007509965A (ja) *	2003-10-29	2007-04-19	タワコル，レイフ	Ｈｄｌ及びｈｄｌ−２ｂレベルを高めるための組成物及び方法
CA2610854A1 (en) *	2005-03-30	2006-10-05	Sirtris Pharmaceuticals, Inc.	Nicotinamide riboside and analogues thereof
US20070014833A1 (en) *	2005-03-30	2007-01-18	Sirtris Pharmaceuticals, Inc.	Treatment of eye disorders with sirtuin modulators
US20060292099A1 (en) *	2005-05-25	2006-12-28	Michael Milburn	Treatment of eye disorders with sirtuin modulators
US20070149466A1 (en) *	2005-07-07	2007-06-28	Michael Milburn	Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
WO2007074406A2 (en) *	2005-07-11	2007-07-05	Pharmena North America Inc.	Formulations for treatment of lipoprotein abnormalities comprising a statin a statin and a methylnicotinamide derivative
KR20070063350A (ko) *	2005-12-14	2007-06-19	주식회사종근당	서방형 방출층과 속방형 방출층을 포함한 고지혈증 및동맥경화를 치료를 위한 약제학적 조성물
CA2569776A1 (en) *	2006-02-17	2007-08-17	Kos Life Sciences, Inc.	Low flush niacin formulation
JP5628480B2 (ja) *	2006-03-09	2014-11-19	グラクソスミスクラインエルエルシー	医薬成分を含有するコーティングカプセル
US8784886B2 (en)	2006-03-09	2014-07-22	GlaxoSmithKline, LLC	Coating capsules with active pharmaceutical ingredients
WO2008023958A1 (en) *	2006-08-24	2008-02-28	Hanall Pharmaceutical Co., Ltd.	Combined pharmaceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
WO2008023869A1 (en) *	2006-08-24	2008-02-28	Hanall Pharmaceutical Co., Ltd.	Combined pharmeceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
DE102007003524A1 (de) *	2007-01-19	2008-09-04	MEDICE Arzneimittel Pütter GmbH & Co. KG	Arzneimittel zur Behandlung und/oder Prävention von Arteriosklerose
KR100885029B1 (ko) *	2007-02-07	2009-02-23	지엘팜텍 주식회사	경구투여용 서방성 삼중정제
WO2009016577A2 (en) *	2007-07-27	2009-02-05	Ranbaxy Laboratories Limited	A pharmaceutical composition comprising atorvastatin and niacin
CN102014881A (zh) *	2008-02-22	2011-04-13	韩兀生物制药株式会社	药物制剂
KR100949273B1 (ko) *	2008-02-22	2010-03-25	한올제약주식회사	복합제제
US20110052683A1 (en) *	2008-02-22	2011-03-03	Hanall Biopharma Co., Ltd.	Pharmaceutical preparation for treating cardiovascular disease
NZ589469A (en) *	2008-05-20	2012-08-31	Cerenis Therapeutics Holding S A	Niacin and NSAID combination for reducing niacin-induced flushing
US20110123575A1 (en) *	2008-06-02	2011-05-26	Dr. Reddy's Laboratories Ltd.	Modified release niacin formulations
RU2010153904A (ru) *	2008-06-02	2012-07-20	Др. Редди'С Лабораторис Лтд. (In)	Ниацин-содержащие композиции с модифицированным высвобождением
US20100178341A1 (en) *	2008-06-11	2010-07-15	Ranbaxy Laboratories Limited	BILAYERED TABLET COMPRISING NIACIN AND HMG-CoA REDUCTASE INHIBITOR
WO2010005581A1 (en) *	2008-07-11	2010-01-14	Kareus Therapeutics, Llc	Niacin compositions for reduction of amyloid beta peptide 42 (abeta 42) production and for treatment of alzheimer's disease (ad)
JP5845173B2 (ja) *	2009-05-01	2016-01-20	アデアファーマスーティカルズ，インコーポレイテッド	非オピオイドおよびオピオイド鎮痛薬の組み合わせを含む口腔内崩壊錠組成物
CA2706270C (en) *	2010-06-03	2020-01-07	Accucaps Industries Limited	Pharmaceutical formulations of statins and omega-3 fatty acids for encapsulation
KR20200003219A (ko)	2011-05-20	2020-01-08	아스트라제네카 유케이 리미티드	로수바스타틴 칼슘의 약학 조성물
RU2017118432A (ru)	2014-11-14	2018-12-14	Джемфир Терапьютикс Инк.	СПОСОБЫ И ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ ДЛЯ ПОЛУЧЕНИЯ ДИАЛКАНОВЫХ ЭФИРОВ, СОДЕРЖАЩИХ КОНЦЕВУЮ α,ω-ДИКАРБОНОВОКИСЛОТНУЮ ГРУППУ
CN108366957A (zh) *	2015-11-06	2018-08-03	燿石治疗公司	用于治疗心血管疾病的吉卡宾组合
IL269884B2 (en)	2017-04-18	2023-09-01	Gemphire Therapeutics Inc	Gamkaban its accepted pharmaceutical salts, their compositions and methods of their use

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3524001A (en) *	1965-03-04	1970-08-11	Upjohn Co	Compositions and method for reducing free fatty acid and cholesterol in the blood of mammals with 3,5 - disubstituted isoxazoles
JPS63310827A (ja) *	1987-06-15	1988-12-19	Sanwa Kagaku Kenkyusho Co Ltd	ニコチン酸誘導体を主剤とする徐放性製剤
US5260305A (en) *	1988-12-12	1993-11-09	E. R. Squibb & Sons, Inc.	Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination
US4933165A (en) *	1989-01-18	1990-06-12	Merck & Co., Inc.	Coenzyme Q10 with HMG-CoA reductase inhibitors
US5268181A (en) *	1989-04-13	1993-12-07	Upsher-Smith Laboratories, Inc.	Method of using niacin to control nocturnal cholesterol synthesis
CA2016467A1 (en) *	1989-06-05	1990-12-05	Martin Eisman	Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
CA2018470A1 (en) *	1989-07-17	1991-01-17	Scott Adams Biller	Phosphorus-containing squalene synthetase inhibitors and method
US5135935A (en) *	1991-05-17	1992-08-04	Merck & Co., Inc.	Squalene synthetase inhibitors
US5840339A (en) *	1991-07-30	1998-11-24	Kunin; Robert	Blood cholesterol reducing pharmaceutical composition
JPH07504887A (ja) *	1991-11-22	1995-06-01	リポジェニックス，インコーポレイテッド	トコトリエノールおよびトコトリエノール様化合物ならびにこれらを使用する方法
US5292534A (en) *	1992-03-25	1994-03-08	Valentine Enterprises, Inc.	Sustained release composition and method utilizing xanthan gum and an active ingredient
US5609884A (en) *	1992-08-31	1997-03-11	G. D. Searle & Co.	Controlled release naproxen sodium plus naproxen combination tablet
US6129930A (en) *	1993-09-20	2000-10-10	Bova; David J.	Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6080428A (en) *	1993-09-20	2000-06-27	Bova; David J.	Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6369103B1 (en) *	1994-01-18	2002-04-09	Bristol-Myers Squibb Company	Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
US5582838A (en) *	1994-12-22	1996-12-10	Merck & Co., Inc.	Controlled release drug suspension delivery device
EP0821587A4 (de) *	1995-04-19	1999-05-19	Lipoprotein Technologies Inc	Mittel, kits und verfahren zur verabreichung von antilipämischen und gegen die blutplättchen-aggregation wirkenden arzneistoffen
US5773453A (en) *	1995-04-19	1998-06-30	Vanderbilt University	Methods for administration of antilipemic drugs

1998
- 1998-07-31 DK DK98938228T patent/DK1017390T3/da active
- 1998-07-31 IL IL13427198A patent/IL134271A0/xx active IP Right Grant
- 1998-07-31 DE DE69837610T patent/DE69837610T2/de not_active Expired - Lifetime
- 1998-07-31 WO PCT/US1998/015990 patent/WO1999006035A2/en not_active Ceased
- 1998-07-31 CA CA002298549A patent/CA2298549C/en not_active Expired - Lifetime
- 1998-07-31 ES ES07003276T patent/ES2336492T3/es not_active Expired - Lifetime
- 1998-07-31 ES ES98938228T patent/ES2283067T3/es not_active Expired - Lifetime
- 1998-07-31 AT AT07003276T patent/ATE451926T1/de not_active IP Right Cessation
- 1998-07-31 DE DE69841395T patent/DE69841395D1/de not_active Expired - Lifetime
- 1998-07-31 EP EP98938228A patent/EP1017390B1/de not_active Expired - Lifetime
- 1998-07-31 AT AT98938228T patent/ATE359785T1/de active
- 1998-07-31 EP EP07003276A patent/EP1792616B1/de not_active Expired - Lifetime
- 1998-07-31 AU AU86801/98A patent/AU752673B2/en not_active Ceased
- 1998-07-31 NZ NZ520176A patent/NZ520176A/en not_active IP Right Cessation
- 1998-07-31 BR BR9815548-2A patent/BR9815548A/pt not_active Application Discontinuation
- 1998-07-31 JP JP2000504849A patent/JP4870869B2/ja not_active Expired - Fee Related
- 1998-07-31 PT PT98938228T patent/PT1017390E/pt unknown
2000
- 2000-01-27 NO NO20000439A patent/NO20000439L/no not_active Application Discontinuation
- 2000-01-27 IL IL134271A patent/IL134271A/en not_active IP Right Cessation
2003
- 2003-09-02 US US10/260,027 patent/US20040053975A1/en not_active Abandoned
2007
- 2007-05-07 CY CY20071100604T patent/CY1107057T1/el unknown
2009
- 2009-02-27 US US12/394,441 patent/US20090226518A1/en not_active Abandoned
- 2009-07-22 JP JP2009170721A patent/JP2009235105A/ja active Pending
2011
- 2011-10-27 US US13/282,755 patent/US20120164221A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CA2298549A1 (en)	1999-02-11
HK1106153A1 (en)	2008-03-07
US20040053975A1 (en)	2004-03-18
CA2298549C (en)	2006-01-10
JP4870869B2 (ja)	2012-02-08
AU752673B2 (en)	2002-09-26
ES2336492T3 (es)	2010-04-13
NZ520176A (en)	2005-02-25
NO20000439L (no)	2000-03-22
DE69841395D1 (de)	2010-01-28
AU8680198A (en)	1999-02-22
DK1017390T3 (da)	2007-06-11
JP2009235105A (ja)	2009-10-15
WO1999006035A2 (en)	1999-02-11
IL134271A (en)	2006-07-05
PT1017390E (pt)	2007-07-24
EP1792616A1 (de)	2007-06-06
US20120164221A1 (en)	2012-06-28
ES2283067T3 (es)	2007-10-16
IL134271A0 (en)	2001-04-30
WO1999006035A3 (en)	1999-04-22
DE69837610T2 (de)	2008-01-03
EP1792616B1 (de)	2009-12-16
EP1017390A2 (de)	2000-07-12
CY1107057T1 (el)	2012-10-24
BR9815548A (pt)	2000-11-07
NO20000439D0 (no)	2000-01-27
DE69837610D1 (de)	2007-05-31
EP1017390B1 (de)	2007-04-18
US20090226518A1 (en)	2009-09-10
JP2001511444A (ja)	2001-08-14
ATE451926T1 (de)	2010-01-15

Legal Events

Date

Code

Title

Description

2007-09-15

UEP

Publication of translation of european patent specification

Ref document number: 1017390

Country of ref document: EP

Publication	Publication Date	Title
ATE359785T1 (de)	2007-05-15	Manteltablette enthaltend nikotinsäure oder einen stoff, der zu nikotinsäure metabolisiert wird, in verzögert freigesetzter form, und einen hmg-coa reduktasehemmer im mantel zur sofortigen freisetzung
NO973814D0 (no)	1997-08-19	Basisk stabilisert sammensetning av HMG-CoA-reduktase inhibitor
CA2297764A1 (en)	1999-02-11	Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia
HUP0401714A2 (hu)	2004-12-28	Propiverin vagy gyógyászatilag elfogadható sóinak nyújtott hatóanyag-eladású, orális adagolási formái
SG98436A1 (en)	2003-09-19	Method of forming an active-element containing aluminide as stand alone coating and as bond coat and coated article
CA2315927A1 (en)	1999-07-01	Oral pharmaceutical pulsed release dosage form
IE970731A1 (en)	2000-10-04	Product and method for the treatment of hyperlipidemia
BR9609220A (pt)	1999-06-08	Composição formadora de película aderente métodos para aplicar um revestimento composto a um substrato e para reparar um revestimento composto de cor mais incolor e artigo revestido
NZ240946A (en)	1993-09-27	Substituted pyridyl-dihydroxy-heptenoic acid and amides thereof: preparation and medicaments thereof
CA2433283A1 (en)	2002-07-04	Chewing gums and related products that provide breath freshening characteristics
MX9402938A (es)	1995-01-31	Composicion terapeutica que comprende nicotinamida-adenina-dinucleotido ynicotinamida-adenina-fosfato-dinucleotido, estable ingerible y absorbible.
CA2334120A1 (en)	2000-02-24	Oral sustained-release preparation of fasudil hydrochloride
AU1943795A (en)	1995-10-03	Low friction cobalt-based coatings for titanium
EP0787477A3 (de)	1998-12-09	Adhäsive
EP0773022A3 (de)	1999-05-12	Pharmazeutische Zubereitung zur Behandlung akuter Rhinitiden, enthaltend Sympthomimeticum und Pantothenol und/oder Pantothensäure
WO2004021972A3 (en)	2004-08-12	Pharmaceuticals formulations and methods for modified release of statin drugs
CA2340054A1 (en)	2000-02-24	Oral administration form for pyridin-2-ylmethylsulfinyl-1h-benzimidazoles
BR0317520A (pt)	2005-11-16	Composições de inibidores de proteìna de transferência de ésteres de colesterilo e inibidores de hmg-coa redutase
NO996049L (no)	2000-02-07	Farmasoeytisk preparat med kontrollert frigjoering, med ACE- inhibitor som aktiv ingrediens
TR200003558A2 (tr)	2001-07-23	Yüksek derecede kaynatılmış şekerlemelerin yapışkanlığının önlenmesi
AU7101691A (en)	1991-08-29	Quinoline and pyridine anchors for hmg-coa reductase inhibitors
AU1435888A (en)	1988-10-13	Binder-free granules with delayed release of the active compound
WO1999042087A3 (en)	1999-11-25	Controlled release potassium chloride pellet based pharmaceutical compositions having a high active ingredient content
AU637321B2 (en)	1993-05-27	Quinoline and pyridine anchors for a hmg-coa reductase inhibitors
AU4856996A (en)	1996-08-14	Crystalline composition of lysine and succinic acid or alkali metal salt thereof